VYLOY Approval Forces Rethink on Biomarker-Gated IV Oncology Manufacturing

Astellas Pharma US has secured FDA approval for VYLOY (zolbetuximab-clzb), a CLDN18.2-directed cytolytic antibody for first-line treatment of unresectable or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Approved on October 18, 2024, the product's mandatory CLDN18.2-positive, HER2-negative patient selection criteria places companion diagnostic integration squarely within the manufacturing and QA workflow, raising process validation and supply chain questions that plant heads and regulatory affairs teams will need to address before commercial scale-up can proceed.

VYLOY is indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy for adults whose tumors are CLDN18.2-positive and HER2-negative and who have not previously received chemotherapy or other anticancer agents. The product is administered as an intravenous infusion every two to three weeks, with dosing interval dependent on the chemotherapy backbone used. That dual-regimen flexibility, mFOLFOX6 or CAPOX, introduces scheduling and fill-finish considerations that IV production teams will need to account for across batch release cycles.

The FDA based its approval on two randomised controlled trials, SPOTLIGHT (NCT03504397) and GLOW (NCT03653507), which together enrolled 1,072 patients with CLDN18.2-positive, HER2-negative gastric or GEJ adenocarcinoma. Trials were conducted across 408 sites in 30 countries spanning Asia, Europe, North America, South America, and Australia. Of the total enrolled population, 74 patients were from the United States. Efficacy endpoints included progression-free survival and overall survival. In SPOTLIGHT, 565 patients were randomised to VYLOY plus mFOLFOX6 or placebo plus mFOLFOX6. In GLOW, 507 patients received VYLOY combined with CAPOX or placebo with CAPOX.

For QA directors and regulatory affairs leads, the biomarker-gated indication model exemplified by VYLOY signals a continued shift toward precision oncology products where patient stratification data must be reliably linked to drug dispensing. Ensuring that CLDN18.2 testing protocols align with prescribing criteria will require close coordination between clinical, diagnostic, and manufacturing functions, particularly as commercial volumes scale beyond the trial's predominantly non-US patient population.

Source: FDA Drug Trials Snapshots: VYLOY, published April 29, 2026, based on original approval date of October 18, 2024. Full prescribing information and approved conditions of use are available via the VYLOY Prescribing Information document.